AR119834A1 - TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN - Google Patents

TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN

Info

Publication number
AR119834A1
AR119834A1 ARP200102397A ARP200102397A AR119834A1 AR 119834 A1 AR119834 A1 AR 119834A1 AR P200102397 A ARP200102397 A AR P200102397A AR P200102397 A ARP200102397 A AR P200102397A AR 119834 A1 AR119834 A1 AR 119834A1
Authority
AR
Argentina
Prior art keywords
fully human
diabetic retinopathy
human anti
post translation
vegf fab
Prior art date
Application number
ARP200102397A
Other languages
English (en)
Inventor
Stephen Joseph Pakola
Everen Sherri Van
Jesse I Yoo
Samir Maganbhai Patel
Avanti Arvind Ghanekar
Anthony Ray Oberry
Kim Rees Irwin-Pack
Darin Thomas Curtiss
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Publication of AR119834A1 publication Critical patent/AR119834A1/es

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para la administración de un anticuerpo monoclonal (“mAb”) completamente humano modificado después de la traducción (HuPTM) o el fragmento de unión al antígeno de un mAb contra el factor de crecimiento endotelial vascular humano (“hVEGF”), tal como un fragmento de unión al antígeno anti-hVEGF completamente humano glucosilado (HuGly), en el humor vítreo / retina en los ojos de sujetos humanos con diagnóstico de retinopatía diabética.
ARP200102397A 2019-08-26 2020-08-25 TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN AR119834A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962891799P 2019-08-26 2019-08-26

Publications (1)

Publication Number Publication Date
AR119834A1 true AR119834A1 (es) 2022-01-12

Family

ID=80782124

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102397A AR119834A1 (es) 2019-08-26 2020-08-25 TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN

Country Status (1)

Country Link
AR (1) AR119834A1 (es)

Similar Documents

Publication Publication Date Title
Heier et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies
Weinreb et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study
Rahimy et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema
Kreutzer et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
Ferrari et al. Topical ranibizumab as a treatment of corneal neovascularization
Algvere et al. A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age‐related macular degeneration of different durations
Xue et al. Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia
Rehak et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)
Berger et al. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME
BR112022003811A2 (pt) Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
Ebneter et al. Novelties in diabetic retinopathy
Pichi et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion
JP6944958B2 (ja) 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用
Wakabayashi et al. Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization
Guzel et al. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema
Parravano et al. Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion
Juanarita et al. Dengue related maculopathy and foveolitis
Hanhart et al. Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions
Akıncıoğlu et al. Outcomes of intravitreal dexamethasone implant in the treatment of recalcitrant diabetic macular edema
Moon et al. Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis
Abrishami et al. Treatment of chronic central serous chorioretinopathy with oral methotrexate
AR119834A1 (es) TRATAMIENTO DE RETINOPATÍA DIABÉTICA CON Fab ANTI-VEGF COMPLETAMENTE HUMANO MODIFICADO DESPUÉS DE LA TRADUCCIÓN
Mete et al. Effects of intravitreal bevacizumab (Avastin®) therapy on retrobulbar blood flow parameters in patients with neovascular age‐related macular degeneration
Levy et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration
Kaldırım et al. A comparison study of ranibizumab and aflibercept in patients with naive diabetic macular edema in presence of serous retinal detachment